Pacira Pharmaceuticals Reports Q3 Financial Results

Pharmaceutical Investing

Pacira Pharmaceuticals shared with shareholders its financial results for the third quarter of 2017.

Pacira Pharmaceuticals (NASDAQ:PCRX) shared with shareholders its financial results for the third quarter of 2017.
As quoted in the press release:

“We continue to make important progress during 2017 as we advance our strategy to expand the role of EXPAREL as the only long-acting local analgesic capable of providing non-opioid pain control during the most intense period of postsurgical pain,” said Dave Stack, chairman and chief executive officer of Pacira. “Recent highlights include the FDA acceptance of our sNDA for nerve block; the publication of new research quantifying the devastating impact of opioids for postsurgical pain; a unique collaboration with Aetna to reduce opioid use associated with impacted wisdom teeth extractions; and the advancement of our important partnership with J&J.”
“During the quarter we generated year over year EXPAREL growth despite fewer selling days and the impact of weather in areas of the southern United States representing about 20 percent of our business. From our commercial initiatives and current trends however; we remain confident in the growth potential of EXPAREL and our steadfast commitment to reducing the use of opioids for postsurgical pain.”

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×